Vitis labruscana Bailey leaf extract improves vascular function markers including platelet aggregation: A randomized, double-blind, placebo-controlled trial.

BACKGROUND

Cardiovascular diseases (CVDs) are the leading cause of death worldwide. Platelet aggregation plays a key role in thrombosis, a major contributor to CVD. Previous animal studies suggest that Vitis labruscana Bailey leaf extract (HP-01) may have cardioprotective and antithrombotic effects.

PURPOSE: This study aimed to evaluate the effects of HP-01 supplementation on blood flow-related parameters-such as platelet aggregation (closure time), activated partial thromboplastin time (aPTT), and systolic blood pressure (SBP)-in individuals with CVD risk factors.

STUDY

DESIGN

We conducted a 12-week randomized, double-blind, placebo-controlled trial involving 80 participants with CVD risk factors.

METHODS

Study participants were recruited from the Clinical Trial Center for Functional Foods at Jeonbuk National University Hospital. The participants were randomly assigned to receive HP-01 (1800 mg/day) or a placebo taken thrice for 12 weeks. The endpoints were changes in platelet aggregation, peripheral arterial tonometry index, blood pressure, prothrombin time, activated partial thromboplastin time (aPTT), and lipid profile.

RESULTS

After 12 weeks of supplementation with HP-01, platelet aggregation by closure time was significantly decreased compared with placebo group (122.48±22.94 s to 137.97±51.29 s, p = 0.0252). Moreover, a significant increase of aPTT (31.64±2.64 s to 31.78±2.55 s, p = 0.0402) and a significant decrease in systolic blood pressure (SBP) (127.27±10.12 mmHg to 122.27±11.58 mmHg, p = 0.0398) were observed in the HP-01 group compared with the placebo group. No serious adverse reactions were observed in either group.

CONCLUSIONS

These findings suggest that HP-01 supplementation may contribute to cardiovascular health by improving hemostatic function and lowering blood pressure in individuals with CVD risk factors.